| Methods |
RCT.
Open label.
Active controlled. |
| Participants |
39 participants with POAG.
Racial constitution is not reported.
Inclusion criteria: IOP 22 mmHg or greater, visual field defect in SAP, glaucomatous appearance of optic disc, normal open angle. |
| Interventions |
Timolol 0.5% ophthalmic gel‐forming solution once daily.
Brimonidine 0.2% twice daily. |
| Outcomes |
Change in RNFL thickness (ellipse average, superior average, temporal average, inferior average, nasal average).
IOP. |
| Notes |
Study duration 2 years.
Drop‐out rate: 2 participants on timolol (no adverse event), 3 participants on brimonidine (1 ocular adverse event).
Visual field was examined at baseline only. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
